Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc for HIV PrEP in at-risk MSM and women (NEXT Prep)
NCT01505114Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2012
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of maraviroc in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of Grade 3 or Higher Adverse Events at 48 weeks and Time to permanent regimen discontinuation at 48 weeks. Started Jun 2012; status: completed.
02
Drugs
maraviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01505114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01505114.